Using AI to improve mediastinal ultrasound scans
Official title: Validation of an AI-Assisted Mediastinal EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial
Run by The Third Xiangya Hospital of Central South University · NCT06790108 · Data updated 2026-11-12
This study is testing whether using an AI system during mediastinal ultrasound scans can help doctors get better images and improve diagnosis compared to doing it without AI.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | The Third Xiangya Hospital of Central South University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | January 15, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | June 30, 2026 |
| Registry record updated | January 23, 2025 |
| Trial ID | NCT06790108 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 79 who require endoscopic ultrasonography.
✕Probably not a fit
Patients with severe physical conditions or those who do not consent to participate will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to validate the effectiveness of an artificial intelligence (AI) system in assisting mediastinal endoscopic ultrasound (EUS) procedures. It will compare the image recognition accuracy of the AI system against that of trained EUS endoscopists and assess whether the AI can enhance the quality of the scans performed. Participants will undergo EUS with or without the AI assistance to determine its impact on diagnostic outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved accuracy and quality in mediastinal ultrasound scans, benefiting patients with mediastinal diseases.
How similar studies have gone: While the use of AI in medical imaging is gaining traction, this specific application in mediastinal EUS is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Age ≥18 years old, \<80 years old 2.Patients who need endoscopic ultrasonography; 3. Agree to participate in this study and sign the informed consent form. Exclusion Criteria: Subjects who meet any of the following criteria cannot be selected for this trial: First. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography: Poor physical condition, including hemoglobin ≤8.0g/dl, severe cardiopulmonary insufficiency, etc. Anesthesia assessment failed Pregnancy or breastfeeding In the acute stage of chemical and corrosive injury, it is very easy to cause perforation Recent acute coronary syndrome or clinically unstable ischemic heart attack Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\> 90mmHg), patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome. Second. Disagree to participate in this study. Third. There are other problems that do not meet the requirements of this research or that affect the results of the research: 1. Mediastinal lesions have previously undergone surgery or radiotherapy and chemotherapy; 2. Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.
Where it's running
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China Recruiting
Study contacts
- Principal investigator: Xiaoyan Wang, Doctor — The Third Xiangya Hospital of Central South University
- Study coordinator: Xiaoyan Wang, Doctor
- Email: wangxiaoyan@csu.edu.cn
- Phone: +8613974889301
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma
This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.
-
TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma
This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.
-
Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310
This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.
-
Gene therapy for certain blood cancers
This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.
-
Treatment of relapsed large B-cell lymphoma with WZTL-002 CAR T-cells
This study is testing a new CAR T-cell therapy called WZTL-002 to see if it can help adults with relapsed large B-cell lymphoma that hasn't worked with standard chemotherapy.
-
Observational study on CAR-T therapy for lymphoma in Italy
This study looks at how well CAR-T therapy works and its side effects for people with lymphoma in Italy by tracking their health over three years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.